Print
|
Close
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
Active:
No
Cancer Type:
Melanoma
Unknown Primary
NCT ID:
NCT05002569
Trial Phases:
Phase III
Protocol IDs:
CA224-098 (primary)
NCI-2022-02119
2021-001641-13
Eligibility:
12 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Bristol-Myers Squibb
NCI Full Details:
http://clinicaltrials.gov/show/NCT05002569
Summary
The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC)
versus nivolumab alone in participants with completely resected stage III-IV melanoma.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.